Dermata Therapeutics raises $2.55M in private stock sale to fund research and development.

Dermata Therapeutics, a biotech firm focused on skin diseases, has closed a $2.55 million private placement, issuing 2,007,880 shares of common stock and warrants at $1.27 per share. The funds will support research, clinical trials, technology development, and potential acquisitions. Company insiders, including executives, participated in the offering. H.C. Wainwright & Co. acted as the placement agent.

2 months ago
5 Articles